Xing H Rosie, Campodonico Luis, Kolesnick Richard
Laboratory of Signal Transduction, the Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
J Biol Chem. 2004 Jun 18;279(25):26210-4. doi: 10.1074/jbc.M401323200. Epub 2004 Apr 13.
Kinase Suppressor of Ras1 (KSR1) functions as a positive modulator of Ras-dependent signaling either upstream of or parallel to Raf-1, and pharmacologic inactivation of KSR1 may serve as a treatment for Rasdriven malignancies such as pancreatic cancer (Xing, H. R., Cordon-Cardo, C., Deng, X., Tong, W., Campodonico, L., Fuks, Z., and Kolesnick, R. (2003) Nat. Med. 9, 1266-1268). Although some studies demonstrated a requirement for KSR1 kinase activity for its action, others suggested KSR1 acts primarily as a scaffold facilitating assembly of the c-Raf-1/MEK module. We recently established a two-stage in vitro reconstitution assay to measure KSR1 kinase activity (Xing, H. R., Lozano, J., and Kolesnick, R. (2000) J. Biol. Chem. 275, 17276-17280). In this assay, KSR1, immunopurified to apparent homogeneity, never comes in contact with recombinant kinases other than c-Raf-1. In the first assay stage, activated KSR1 is incubated with recombinant c-Raf-1 and ATP. In the second stage, activated c-Raf-1 is separated from KSR1, and incubated with unactivated MEK1, unactivated MAPK, Elk-1, and ATP. Elk-1 phosphorylation serves as a specific readout for MAPK activation. However, because KSR1 constitutively associates with MEK1 and this interaction appears critical for KSR1 scaffolding function, it has been argued that the kinase activity detected is an artifact of KSR1-bound MEK1. To address these concerns, we depleted as much as 90% of KSR1-bound MEK1 by high salt washing without altering KSR1 kinase activity. Further, a complete inactivation of KSR1-bound MEK1 by pretreating with the MEK inhibitor PD 98059 prior to the first assay stage did not alter KSR1 kinase activity. In addition, the omission of exogenous recombinant GST-MEK1 from the reaction mixture during the second assay stage abolished Elk-1 phosphorylation confirming KSR1-bound MEK1 does not support MAPK activation in our in vitro assay. Moreover, a kinase-inactive mutant, FLAG-Ki-KSR1(D683A/D700A), which efficiently interacts with endogenous MEK1, lacks kinase activity. These results collectively support our contention that the kinase activity of KSR1 is an intrinsic property of this protein independent of KSR1-bound endogenous MEK.
Ras1激酶抑制因子(KSR1)作为Ras依赖性信号传导的正向调节因子,作用于Raf-1的上游或与之平行,KSR1的药理学失活可能可用于治疗Ras驱动的恶性肿瘤,如胰腺癌(邢,H.R.,科登-卡多,C.,邓,X.,童,W.,坎波多尼科,L.,富克斯,Z.,和科尔斯尼克,R.(2003年)《自然医学》9,1266 - 1268)。尽管一些研究表明KSR1激酶活性对其作用是必需的,但其他研究表明KSR1主要作为一种支架促进c-Raf-1/MEK模块的组装。我们最近建立了一种两阶段体外重组测定法来测量KSR1激酶活性(邢,H.R.,洛萨诺,J.,和科尔斯尼克,R.(2000年)《生物化学杂志》275,17276 - 17280)。在该测定法中,免疫纯化至表观均一性的KSR1除了与c-Raf-1外,从不与其他重组激酶接触。在测定的第一阶段,将活化的KSR1与重组c-Raf-1和ATP一起孵育。在第二阶段,将活化的c-Raf-1与KSR1分离,并与未活化的MEK1、未活化的MAPK、Elk-1和ATP一起孵育。Elk-1磷酸化作为MAPK活化的特异性读数。然而,由于KSR1与MEK1组成性结合,并且这种相互作用似乎对KSR1支架功能至关重要,有人认为检测到的激酶活性是KSR1结合的MEK1的假象。为了解决这些问题,我们通过高盐洗涤去除了多达90%的KSR1结合的MEK1,而不改变KSR1激酶活性。此外,在第一测定阶段之前用MEK抑制剂PD 98059预处理使KSR1结合的MEK1完全失活,并没有改变KSR1激酶活性。另外,在第二测定阶段从反应混合物中省略外源性重组GST-MEK1消除了Elk-1磷酸化,证实KSR1结合的MEK1在我们的体外测定中不支持MAPK活化。此外,一种激酶失活突变体,FLAG-Ki-KSR1(D683A/D700A),它能有效地与内源性MEK1相互作用,但缺乏激酶活性。这些结果共同支持了我们的论点,即KSR1的激酶活性是该蛋白的固有特性,独立于KSR1结合的内源性MEK。